
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Description
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Outlook
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of colorectal cancer. It is expected to grow at a CAGR of 6.20% during the forecast period of 2024-2032, with the values likely to attain USD 1492.8 million by 2032.
Key Takeaways
- Recent studies suggest that Asia accounts for 49% of the total number of new cancer cases worldwide, with the incidence and mortality of colorectal cancer likely to reach 1,310,000 and 484,000, respectively, in China by 2044. This rising incidence fuels the demand for effective in-vitro screening tests.
- One of the major Asia Pacific in-vitro colorectal cancer screening tests market trends is the rising technological advancements in in-vitro diagnostic techniques that are leading to the development of minimally invasive screening methods. In February 2023 , researchers from the University of Technology Sydney (UTS) developed an innovative static droplet microfluidic device that can detect cancer cells from blood samples.
- The rise in reimbursement policies ensures the accessibility and affordability of in-vitro screening methods, thereby boosting market size. In July 2023 , the Guardant360® CDx liquid biopsy test developed by Guardant Health, Inc. received reimbursement approval in Japan for comprehensive genomic profiling (CGP) for advanced or metastatic solid tumor cancers.
In-vitro colorectal cancer (CRC) screening tests are diagnostic tests that are performed outside the body of the patient to detect markers or indications associated with colorectal cancer. These screening tests usually involve analyzing biological samples such as stool, blood, or tissue taken from the patient. The rising healthcare expenditure coupled with the heightened awareness regarding cancer screening and importance of early detection is contributing significantly to the Asia Pacific in-vitro colorectal cancer screening tests market growth.
The burden of cancer in Asia Pacific is witnessing a steady increase. Recent studies suggest that Asia accounts for 49% of the total number of new cancer cases worldwide, with half of them found in China. Further, it is estimated that the incidence and mortality of colorectal cancer are likely to reach 1,310,000 and 484,000, respectively, in China by 2044. The increased number of colorectal cancer cases can be attributed to the growing aging populations, sedentary lifestyles, and the prevalence of risk factors such as obesity and smoking. This rising incidence fuels the demand for effective diagnostic tests, which is expected to boost the Asia Pacific in-vitro colorectal cancer screening tests market share in the forecast period.
The continuous technological advancements in in-vitro diagnostic techniques are leading to the development of minimally invasive screening methods. In February 2023 , researchers from the University of Technology Sydney (UTS) developed an innovative static droplet microfluidic device that can detect cancer cells from blood samples. This detection technology reduces the need for invasive biopsies for cancer screening by rapidly identifying tumor cells that enter the bloodstream after breaking away from the primary tumor. Such blood-based assays are gaining popularity due to their accuracy and ease of use and are likely to augment the Asia Pacific in-vitro colorectal cancer screening tests market demand.
The presence of a favorable regulatory environment and reimbursement policies in the region also shapes the market landscape. In July 2023 , the Guardant360® CDx liquid biopsy test developed by Guardant Health, Inc. (a leading precision oncology company) received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for comprehensive genomic profiling (CGP) for advanced or metastatic solid tumor cancers including advanced colorectal cancer patients. The MHLW-approved test analyzes circulating tumor DNA (ctDNA) in a patient’s blood which can offer insights for therapy selection. The rise in reimbursement policies ensures the accessibility and affordability of in-vitro screening methods, thereby boosting the market size for approved diagnostic tests.
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Segmentation
Market Breakup by Testing Type
- Fecal Occult Blood Tests
- Biomarker Tests
- CRC DNA Screening Tests
- Flexible Sigmoidoscopy
- Others
- Colonoscopy
- Proctoscopy
- CT Scan
- Ultrasound
- MRI
- PET Scan
- Hospitals
- Clinics
- Diagnostics Laboratories
- China
- Japan
- India
- ASEAN
- Australia
- Others
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche AG
- Abbott
- Siemens Healthineers AG
- Sysmex Corporation
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Myriad Genetics, Inc.
- Exact Sciences Corporation
FAQs
- What is the Asia Pacific in-vitro colorectal cancer screening tests market forecast outlook for 2024-2032?
- What are the major factors aiding the Asia Pacific in-vitro colorectal cancer screening tests market demand?
- What are the major Asia Pacific in-vitro colorectal cancer screening tests trends?
- What is the market segmentation based on the testing type?
- What is the market breakup by imaging type?
- What are the major end users of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the Asia Pacific in-vitro colorectal cancer screening tests market?
Meta description
Asia Pacific in-vitro colorectal cancer screening tests market is poised for growth, driven by the expansion of the global market, which was valued at USD 920.4 million in 2023, and is projected to grow at a CAGR of 5.53% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Overview
- 3.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
- 3.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
- 4 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Landscape*
- 4.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests: Product Landscape
- 4.2.1 Analysis by Test Type
- 4.2.2 Analysis by Imaging Type
- 5 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
- 6.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 6.1.1 Market Overview
- 6.1.2 Fecal Occult Blood Tests
- 6.1.3 Biomarker Tests
- 6.1.4 CRC DNA Screening Tests
- 6.1.5 Flexible Sigmoidoscopy
- 6.1.6 Others
- 6.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 6.2.1 Market Overview
- 6.2.2 Colonoscopy
- 6.2.3 Proctoscopy
- 6.2.4 CT Scan
- 6.2.5 Ultrasound
- 6.2.6 MRI
- 6.2.7 PET Scan
- 6.3 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Clinics
- 6.3.4 Diagnostics Laboratories
- 6.4 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 6.4.1 Market Overview
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 India
- 6.4.5 ASEAN
- 6.4.6 Australia
- 6.4.7 Others
- 7 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 7.1 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 7.1.1 Market Overview
- 7.1.2 Fecal Occult Blood Tests
- 7.1.3 Biomarker Tests
- 7.1.4 CRC DNA Screening Tests
- 7.1.5 Flexible Sigmoidoscopy
- 7.1.6 Others
- 7.2 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 7.2.1 Market Overview
- 7.2.2 Colonoscopy
- 7.2.3 Proctoscopy
- 7.2.4 CT Scan
- 7.2.5 Ultrasound
- 7.2.6 MRI
- 7.2.7 PET Scan
- 7.3 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospitals
- 7.3.3 Clinics
- 7.3.4 Diagnostics Laboratories
- 8 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 8.1 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 8.1.1 Market Overview
- 8.1.2 Fecal Occult Blood Tests
- 8.1.3 Biomarker Tests
- 8.1.4 CRC DNA Screening Tests
- 8.1.5 Flexible Sigmoidoscopy
- 8.1.6 Others
- 8.2 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 8.2.1 Market Overview
- 8.2.2 Colonoscopy
- 8.2.3 Proctoscopy
- 8.2.4 CT Scan
- 8.2.5 Ultrasound
- 8.2.6 MRI
- 8.2.7 PET Scan
- 8.3 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospitals
- 8.3.3 Clinics
- 8.3.4 Diagnostics Laboratories
- 9 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 9.1 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 9.1.1 Market Overview
- 9.1.2 Fecal Occult Blood Tests
- 9.1.3 Biomarker Tests
- 9.1.4 CRC DNA Screening Tests
- 9.1.5 Flexible Sigmoidoscopy
- 9.1.6 Others
- 9.2 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 9.2.1 Market Overview
- 9.2.2 Colonoscopy
- 9.2.3 Proctoscopy
- 9.2.4 CT Scan
- 9.2.5 Ultrasound
- 9.2.6 MRI
- 9.2.7 PET Scan
- 9.3 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospitals
- 9.3.3 Clinics
- 9.3.4 Diagnostics Laboratories
- 10 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 10.1 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 10.1.1 Market Overview
- 10.1.2 Fecal Occult Blood Tests
- 10.1.3 Biomarker Tests
- 10.1.4 CRC DNA Screening Tests
- 10.1.5 Flexible Sigmoidoscopy
- 10.1.6 Others
- 10.2 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 10.2.1 Market Overview
- 10.2.2 Colonoscopy
- 10.2.3 Proctoscopy
- 10.2.4 CT Scan
- 10.2.5 Ultrasound
- 10.2.6 MRI
- 10.2.7 PET Scan
- 10.3 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospitals
- 10.3.3 Clinics
- 10.3.4 Diagnostics Laboratories
- 11 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 11.1 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 11.1.1 Market Overview
- 11.1.2 Fecal Occult Blood Tests
- 11.1.3 Biomarker Tests
- 11.1.4 CRC DNA Screening Tests
- 11.1.5 Flexible Sigmoidoscopy
- 11.1.6 Others
- 11.2 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 11.2.1 Market Overview
- 11.2.2 Colonoscopy
- 11.2.3 Proctoscopy
- 11.2.4 CT Scan
- 11.2.5 Ultrasound
- 11.2.6 MRI
- 11.2.7 PET Scan
- 11.3 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Clinics
- 11.3.4 Diagnostics Laboratories
- 12 Regulatory Framework
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 F. Hoffmann-La Roche AG
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Abbott
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Siemens Healthineers AG
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Sysmex Corporation
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 Beckman Coulter, Inc.
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Bio-Rad Laboratories, Inc
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Qiagen NV
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 Thermo Fisher Scientific Inc.
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Myriad Genetics, Inc.
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 Exact Sciences Corporation
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 16 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.